Congenital Disorders of Glycosylation
Gene: SLC26A2
Gene-disease association is well-established (OMIM, PMID:11241838) but I can find no evidence that it plays a direct role in glycosylation.
SLC26A2 encodes a membrane glycoprotein which functions as a sulfate transporter.
From GeneReviews: "Three autosomal recessive disorders, diastrophic dystrophy (DTD), atelosteogenesis type II (AOII), and achondrogenesis type IB (ACG-IB), all result from defective cartilage proteoglycan sulfation...All of these disorders result from different mutations in the DTD gene (SLC26A2), which encodes a plasma membrane sulfate transporter...the heavy demand for sulfate in bone and cartilage proteoglycan synthesis probably explains why the symptoms are most evident in these locations." (https://www.ncbi.nlm.nih.gov/books/NBK453041/)
SLC26A2 is on the Invitae and Mayo Clinic CDG panels. It is listed as a CDG gene on https://glycosmos.org/gdgdbs/indexCreated: 22 Jul 2020, 1 a.m. | Last Modified: 22 Jul 2020, 1:06 a.m.
Panel Version: 0.96
Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal
Phenotypes
Skeletal dysplasia (various)
Publications
Variants in this GENE are reported as part of current diagnostic practice
Gene: slc26a2 has been classified as Amber List (Moderate Evidence).
Phenotypes for gene: SLC26A2 were changed from to Skeletal dysplasia (various)
Publications for gene: SLC26A2 were set to
Mode of inheritance for gene: SLC26A2 was changed from Unknown to BIALLELIC, autosomal or pseudoautosomal
Gene: slc26a2 has been classified as Amber List (Moderate Evidence).
gene: SLC26A2 was added gene: SLC26A2 was added to Congenital Disorders of Glycosylation_VCGS. Sources: Expert Review Green,Victorian Clinical Genetics Services Mode of inheritance for gene: SLC26A2 was set to Unknown